STOCKSCOPE

The Calmer Co (ASX: CCO): A $25 Million Kava Opportunity as Supermarket Sales Accelerate

Mark Elzayed

Mark Elzayed

CIO at Vestra Capital

Published:23 Oct 2026
The Calmer Co (ASX: CCO): A $25 Million Kava Opportunity as Supermarket Sales Accelerate

The Calmer Co (ASX: CCO) is emerging as an interesting small-cap growth story, with accelerating supermarket sales, a new consumer product launch and international distribution agreements potentially worth millions. As the company expands beyond traditional kava products into mainstream retail and global ingredients supply, investors are beginning to see a broader commercial opportunity taking shape.

The company is positioning itself to capitalise on growing interest in kava, a traditional Pacific Island botanical increasingly marketed through wellness products, functional beverages and alternatives to alcohol.

What has caught our attention is CCO's strategy of combining established supermarket distribution with product innovation and international wholesale opportunities. For a business generating $8.12 million in annual revenue, even modest improvements in consumer adoption could materially change its growth trajectory.

Coles and Woolworths sales are gaining momentum

The latest Australian retail figures suggest CCO's Fiji Kava brand is building traction.

During the September 2026 quarter, sales of established products increased 27% at Coles and 33% at Woolworths compared with the previous quarter, excluding contributions from the new FZZR range.

The company now distributes its 150g root powder through 837 Coles stores, while its 50g product is available across 788 Coles stores and 1,006 Woolworths stores.

Management also reported that Woolworths sales have increased every quarter since the national launch in June 2025, with September delivering its strongest monthly performance.

For investors, the opportunity is shifting from securing supermarket shelf space to generating higher sales from an already extensive national distribution network.

If consumer awareness and repeat purchasing continue improving, CCO could increase revenue without requiring a proportionate expansion in retail outlets.

FZZR could unlock a new consumer market

October marks another commercial milestone with the rollout of FZZR Piña Colada 10-packs across 583 Coles stores.

Unlike traditional kava powders, FZZR uses an effervescent format that can be dissolved in water, consumed directly or chewed.

The product targets convenience and accessibility, potentially introducing kava to consumers who might otherwise overlook conventional preparations.

The scale of the opportunity becomes clearer when considering supermarket volumes.

If each participating Coles store sold just five packs weekly, annualised sales could reach approximately 151,580 packs, assuming full-year availability across the network.

While illustrative rather than a forecast, this demonstrates how relatively modest consumer demand could generate meaningful volume.

The crucial test will be whether initial purchases translate into repeat orders.

International agreements could transform revenue potential

Beyond Australia, CCO is developing an ingredients supply business that could significantly broaden its revenue base.

An August distribution agreement covers Australia, New Zealand, the United States, Canada and ASEAN markets, with exclusivity conditional on approximately $25 million in purchases over three years, including $5.5 million during the first agreement year.

These thresholds are not guaranteed revenue, but their potential scale is significant relative to CCO's existing business.

A separate US beverage supply agreement also anticipates approximately $2 million in annual sales, supported by a minimum commitment of $1.582 million over two years.

Meanwhile, CCO has appointed VDriven to support expansion into US natural, organic and specialty retail.

The broader opportunity is for CCO to become both a consumer-facing kava brand and an international ingredients supplier, creating multiple channels for growth.

Can stronger sales finally deliver profitability?

The financial position remains the most important consideration.

FY26 revenue reached $8.12 million, while gross profit declined to $2.87 million, reflecting a reduction in gross margin from 42.5% to 35.3%.

Nevertheless, operating cash outflow improved 32.8% to $2.94 million, suggesting progress in controlling cash consumption.

With $669,000 in cash at June 2026 and subsequent capital raising activity, funding remains an important execution risk.

The potential upside becomes clearer under a higher-volume scenario.

At $13 million in annual revenue and a 40% gross margin, CCO could generate approximately $5.2 million in gross profit, an improvement of $2.33 million over FY26.

That would not guarantee profitability, but it could substantially improve the company's ability to cover operating expenses.

Our view: A speculative growth opportunity worth watching

We believe CCO is entering an important phase as its strategy moves from establishing distribution towards converting that access into recurring revenue.

The Australian supermarket momentum is encouraging, while FZZR and international ingredients agreements provide additional growth opportunities.

However, repeat consumer demand, margin recovery and sufficient working capital will ultimately determine whether the company can deliver sustainable earnings.

We will be watching FZZR replenishment orders, US retail commitments and actual international ingredients deliveries throughout 2027.

For speculative small-cap investors, CCO presents an interesting opportunity, but the next meaningful improvement in its investment case must come from financial performance, not simply expanding distribution.

Download The Calmer Co Initiation Report

Want to explore the investment opportunity in greater detail? The Calmer Co (ASX: CCO) Initiation Report, dated 18 October 2026, examines the company's growth strategy, supermarket expansion, international supply agreements, financial position and illustrative valuation scenarios.

Download the Full Initiation Report (PDF)

Access our comprehensive equity research to understand the opportunities, financial assumptions and key risks shaping CCO's investment outlook.

Mark Elzayed

Mark Elzayed

(CIO at Vestra Capital)

Mark Elzayed is a prominent Australian financial executive and portfolio strategist with over a decade of hands-on capital markets experience. Having successfully managed over $100M+ in FUM across volatile economic cycles, Mark founded Vestra Capital to democratize institutional-grade quantitative strategies and privileged ASX deal flow for Australian investors.

DisclaimerInformation on Stockscope is general in nature and does not constitute financial product advice. It does not take into account your personal objectives, financial situation or needs. Seek independent advice from a qualified financial adviser before making an investment decision. Stockscope and its affiliates do not guarantee the accuracy or completeness of information published on this website. To the extent permitted by law, they accept no liability for any claim, loss or damage arising from its use or reliance on it. Stockscope and its associates may have commercial relationships with companies featured on this website, hold securities in those companies, or receive commissions in connection with capital raisings.

Continue Reading

ASX Weathers Wall Street's AI Rout, but Three Market Risks Are Becoming Harder to Ignore
Market Briefings
Market Briefings

ASX Weathers Wall Street's AI Rout, but Three Market Risks Are Becoming Harder to Ignore

Australian equities: what moved the ASX 200? Australian shares finished lower on Friday, 6 November, as the technology-led sell-off on Wall Street spread across global markets. The ASX 200...

Mark ElzayedMark Elzayed•
Epiminder (ASX: EPI) Expands FDA Clearance as $65 Million Cash Reserve Faces a Crucial Commercial Test
Biotech & Health
Biotech & Health

Epiminder (ASX: EPI) Expands FDA Clearance as $65 Million Cash Reserve Faces a Crucial Commercial Test

Epiminder Limited ASX: EPI has expanded the US market for its epilepsy monitoring technology following a significant regulatory clearance, strengthening its commercial prospects ahead of a p...

Danny AadDanny Aad•
Asara Resources (ASX: AS1) Hits 38m at 2.1g/t Gold: Could Sogosogoba Unlock Kada's Next Growth Phase?
Mining
Mining

Asara Resources (ASX: AS1) Hits 38m at 2.1g/t Gold: Could Sogosogoba Unlock Kada's Next Growth Phase?

A 38-metre gold intersection grading 2.1 grams per tonne has given Asara Resources Limited ASX: AS1 an encouraging exploration result beyond its established Massan deposit in Guinea. The dis...

Alison ElzayedAlison Elzayed•
Alvo Minerals (ASX: ALV) Expands Rare Earth Discovery Across 6.5km², but Can It Deliver Economic Value?
Mining
Mining

Alvo Minerals (ASX: ALV) Expands Rare Earth Discovery Across 6.5km², but Can It Deliver Economic Value?

Alvo Minerals Limited ASX: ALV has extended rare earth mineralisation approximately 2 kilometres beyond previously tested areas at its Boa Vista prospect in Brazil, strengthening the explora...

Alison ElzayedAlison Elzayed•
Avenira Limited (ASX: AEV) Raises $48.9 Million as Wonarah Phosphate Project Faces Its Biggest Test Yet
Mining
Mining

Avenira Limited (ASX: AEV) Raises $48.9 Million as Wonarah Phosphate Project Faces Its Biggest Test Yet

Avenira Limited ASX: AEV has reached a significant financing milestone, with its $48.9 million rights issue providing fresh capital to advance the Wonarah Phosphate Project in the Northern T...

Alison ElzayedAlison Elzayed•
Mayne Pharma Group (ASX: MYX) Unveils $55.5 Million Sale, but Can Its US Business Deliver Stronger Profits?
Biotech & Health
Biotech & Health

Mayne Pharma Group (ASX: MYX) Unveils $55.5 Million Sale, but Can Its US Business Deliver Stronger Profits?

Mayne Pharma Group Limited ASX: MYX is taking a decisive step towards becoming a US-focused pharmaceutical company, agreeing to sell its international operations for $55.5 million. The tran...

Danny AadDanny Aad•
Loading more stories...